Submitted by Anonymous (not verified) on 6 June 2025 - 16:29
Opinion/decision on a Paediatric investigation plan (PIP): Rybrevant, amivantamab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0166/2024
Source: